Clinical and out-of-pocket cost outcomes after switching to biosimilar adalimumab-atto in patients with rheumatoid arthritis
These results provide evidence that switching from RP adalimumab to biosimilar adalimumab-atto did not result in disease worsening or increased adverse events but did deliver modestly lower patient out-of-pocket costs.
Authors
- Rita L. Hui (ORCID: https://orcid.org/0000-0003-0014-2431)
- Fang Niu (ORCID: https://orcid.org/0009-0004-3439-7410)
- Catherine Pham (ORCID: https://orcid.org/0009-0001-8156-374X)
- Thomas Delate (ORCID: https://orcid.org/0000-0002-6530-8415)
- Samantha S.M. Teshima
- Antony T. Lin
- Abbey Londa
Institutions
- Kaiser Permanente (US)
- Colorado Permanente Medical Group (US)
- Center for Rheumatology (US)
Publication Details
- Journal
- Expert Opinion on Biological Therapy
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1080/14712598.2025.2574011
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00